SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-150715"
 

Search: onr:"swepub:oai:DiVA.org:umu-150715" > Effect of simvastat...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hodges, Gethin W. (author)

Effect of simvastatin and ezetimibe on suPAR levels and outcomes

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • ELSEVIER IRELAND LTD,2018
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-150715
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-150715URI
  • https://doi.org/10.1016/j.atherosclerosis.2018.03.030DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background and aims: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with cardiovascular disease. Statins lower both low-density lipoprotein (LDL)-cholesterol and C-reactive protein (CRP), resulting in improved outcomes. However, whether lipid-lowering therapy also lowers suPAR levels is unknown.& para;& para;Methods: We investigated whether treatment with Simvastatin 40 mg and Ezetimibe 10 mg lowered plasma suPAR levels in 1838 patients with mild-moderate, asymptomatic aortic stenosis, included in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, using a pattern mixture model. A 1-year Cox analysis, adjusted for established cardiovascular risk factors, allocation to study treatment, peak aortic valve velocity and baseline suPAR, was performed to evaluate relationships between change in suPAR with all-cause mortality and the composite endpoint of major cardiovascular events (MCE) composed of ischemic cardiovascular events (ICE) and aortic valve related events (AVE).& para;& para;Results: After 4.3 years of follow-up, suPAR levels had increased by 9.2% (95% confidence interval [CI]: 7.0%-11.5%) in the placebo group, but only by 4.1% (1.9%-6.2%) in the group with lipid-lowering treatment (p<0.001). In a multivariate 1-year analysis, 1-year suPAR was strongly associated with all-cause mortality, hazard ratio (HR) = 2.05 (1.17-3.61); MCE 1.40 (1.01-1.92); and AVE 1.42 (1.02-1.99) (all p<0.042) for each doubling of suPAR; but was not associated with ICE.& para;& para;Conclusions: Simvastatin and Ezetimibe treatment impeded the progression of the time-related increase in plasma suPAR levels. Year-1 suPAR was associated with all-cause mortality, MCE, and AVE irrespective of baseline levels (SEAS study: NCT00092677). (C) 2018 Elsevier B.V. All rights reserved.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bang, Casper N. (author)
  • Forman, Julie L. (author)
  • Olsen, Michael H. (author)
  • Boman, KurtUmeå universitet,Medicin(Swepub:umu)kubo0001 (author)
  • Ray, Simon (author)
  • Kesaniemi, Y. Antero (author)
  • Eugen-Olsen, Jesper (author)
  • Greve, Anders M. (author)
  • Jeppesen, Jorgen L. (author)
  • Wachtell, Kristian (author)
  • Umeå universitetMedicin (creator_code:org_t)

Related titles

  • In:Atherosclerosis: ELSEVIER IRELAND LTD272, s. 129-1360021-91501879-1484

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view